(Q34275202)

1 August 2017

1 reference

title

Oxcarbazepine, an antiepileptic agent (English)

1 reference

1 August 2017

M M Kalis

1

1 reference

PubMed ID

11394728

1 August 2017

N A Huff

series ordinal

2

1 reference

1 August 2017

1 May 2001

1 reference

1 August 2017

Clinical Therapeutics

1 reference

1 August 2017

23

1 reference

1 August 2017

5

1 reference

1 August 2017

680-700; discussion 645

1 reference

The cost of epilepsy in the United States: an estimate from population-based clinical and survey data

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Seizure disorders: the changes with age.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Safety and efficacy of oxcarbazepine: results of randomized, double-blind trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Oxcarbazepine: mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

1 reference

7 January 2021

Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Voltage-activated calcium channels: targets of antiepileptic drug therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Antiepileptic drug mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Place of newer antiepileptic drugs in the treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

The clinical pharmacokinetics of the new antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Oxcarbazepine disposition: preliminary observations in patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Antiepileptic drug pharmacokinetics and interactions: impact on treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Pharmacokinetic interactions of the new antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Therapeutic monitoring of the new antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Oxcarbazepine: Double-blind, randomized, placebo-control, monotherapy trial for partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Oxcarbazepine in the treatment of early childhood epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Treatment of epilepsy in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Trigeminal neuralgia : a guide to drug choice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

The place of anticonvulsant therapy in bipolar illness

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Oxcarbazepine for panic disorder occurring after two grand mal seizures: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Monotherapy trials of new antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Hyponatraemia during oxcarbazepine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Hyponatremic coma under oxcarbazepine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Elimination of oxcarbazepine-induced oculogyric crisis following vagus nerve stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Absence of interaction between oxcarbazepine and erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Oxcarbazepine does not interact with cimetidine in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Oxcarbazepine does not affect the anticoagulant activity of warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Monostars: an aid to choosing an antiepileptic drug as monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

Treatment of epilepsy in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

The distribution of 10-hydroxy carbazepine in blood compartments

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980019-9

7 January 2021

10.1016/S0149-2918(01)80019-9

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11394728